Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Call to Schedule Free Consultation at Over 45 Centers Worldwide!
R3 Stem Cell: Affordable, High-Quality Parkinson’s Treatment.
Free Download: Stem Cell Therapy for Autism
Disclaimer:
The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.
Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.
Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help for Parkinson’s Disease (PD). Spoiler alert: It can help a lot! In this guide, we’ll go through the basics of how stem cells and exosomes work for PD, the latest research, and what to expect with a regenerative procedure.
Conventional treatments for PD are often not able to regenerate and repair neurons or halt progression significantly. There has therefore been a keen interest in stem cell therapy, as it may actually slow down or repair the underlying disease process.
Slow Parkinson’s progression with stem cells. (844) GET-STEM for expert guidance.
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder characterized by the loss of specific populations of neurons and the accumulation of protein aggregates in the brain. The disease affects more than 1% of the population over the age of 60, and as the population ages this frequency is likely to increase.
Its main clinical manifestations are motor dysfunctions, including tremor, bradykinesia, rigidity and postural instability. However, many non‐motor symptoms may precede years before motor Symptoms. Olfactory impairment is one of the most common and characteristic non‐motor features of PD, with a prevalence of 50–90%.
Motor impairment in patients with PD is common and increases markedly with age. The most common symptom of PD is tremor, which usually occurs at rest but decreases with voluntary movement. Additional non motor symptoms include hyposmia, constipation, anxiety, depression, orthostatic hypotension, urinary dysfunction, rapid eye movement sleep behavior disorder, and cognitive dysfunction. A proportion of PD patients also develop mental health problems, such as depression and dementia. PD with dementia often develops years after the onset of motor dysfunction and is estimated in 30–80% of affected individuals.
Currently, we can distinguish at least three main types of this disease. In the first type—sporadic, in which the cause of the disease is unknown, we can only assume a nucleotide change in some genes, but their direct effect is not specified.
The second type—environmental, is the effect of chemical poisons known for years, which specifically destroy dopaminergic neurons. The third type— familial Parkinson’s disease- is caused by a specific mutation in one of the genes: alpha-synuclein, parkin, ubiquitin L1 hydrolase, and PINK1 kinase. The protein kinase PINK1 is involved in the control of the state of the mitochondria. It manifests itself in a constantly progressive disturbance of motor functions.
Fight Parkinson’s with proven science. Contact us at (844) GET-STEM Today
While there are no disease-modifying treatments for PD; dopamine replacement therapies (such as carbidopa/levodopa) can help alleviate some of the motor deficits but do not slow or halt the progression of the disease nor do they affect many of the non-motor symptoms. These drugs do not save dopaminergic neurons and prevent disease progression, although they do provide some short‐term improvement in motor function. Dopaminergic neuronal death can have various causes, including oxidative stress, neuroinflammation and mitochondrial damage.
Furthermore, with time they produce their own side effects such as drug-induced dyskinesias and behavioral and neuropsychiatric problems. There has therefore been a keen interest in developing strategies that actually slow down or repair the underlying disease process.
Many current PD therapies only deal with symptoms, not the neurodegeneration underlying Parkinson’s disease. Several medications can help manage the symptoms of Parkinson’s disease. These include levodopa, dopamine agonists, MAO-B inhibitors, and COMT inhibitors. Physical therapy can help improve the mobility and balance of people with Parkinson’s disease. It can include exercises to improve muscle strength and coordination and stretching and flexibility exercises.
The neurotrophic factors secreted by mesenchymal stem cells may stimulate differentiation of the resident stem cells and protect regenerated neurons against stress-induced apoptosis (a neuroprotective effect). Initial studies in animals have shown incredible results of MSCs for PD.
In a mouse study evaluating intranasal umbilical cord stem cell exosomes, the exosomes had no trouble crossing the blood–brain barrier, increasing neuronal activity in the olfactory bulb of PD mice, and promoting self-repair mechanisms. This method can save dopaminergic neurons from death, reduce glial activation in the olfactory bulb and substantia nigra region, decrease inflammatory responses, and improve the local microenvironment in PD mice. All these findings support the restoration of olfactory and motor functions in mice with a PD model. The intranasal administration of hUCMSC‐Exos may be a promising strategy for the clinical prevention and early treatment of PD.
In 2020, Boika et al transplanted mesenchymal stem cells to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. The effectiveness of the therapy was evaluated at 1 and 3 months post-transplantation. There was a statistically significant decrease in motor and non motor symptoms in the study group in the post-transplant period. MSCs transplantation was deemed to be a disease-modifying therapeutic strategy in PD.
In 2020, Boika et al transplanted mesenchymal stem cells to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. The effectiveness of the therapy was evaluated at 1 and 3 months post-transplantation. There was a statistically significant decrease in motor and non motor symptoms in the study group in the post-transplant period. MSCs transplantation was deemed to be a disease-modifying therapeutic strategy in PD.
Zhao et al conducted a meta-analysis in 2024, which included nine articles totaling 129 individuals. Stem cell transplantation was an effective treatment for Parkinson’s disease, with neural stem cells, umbilical cord mesenchymal stem cells (UCMSCs), and bone marrow mesenchymal stem cells (BMMSCs) being effective cell sources for transplantation. Stem cell transplantation was shown to be effective for at least 12 months, but its long-term effectiveness remained unknown due to the studies not monitoring patients for more than 1 year.
Data from the controlled trials suggested that stem cell transplantation as a therapy for Parkinson’s disease can be effective for at least 12 months. The factors that may influence its curative effect are time after transplantation and stem cell types.
Stem cells and exosomes act in the body through several mechanisms. They do NOT become part of a patient’s DNA, which means they do not engraft into the person’s existing cells.
They act through:
Stem Cells can also release a huge variety of molecules into the extracellular environment. These molecules, which include extracellular vesicles (exosomes), lipids, free nucleic acids, and soluble proteins, exert crucial roles in repairing damaged tissue. Along with offering stem cells for the treatment of PD, R3 Stem Cell includes stem cell exosomes, which are a type of extracellular vesicle participating in extensive cell-to-cell communication for central nervous system tissue repair and regeneration.
The stem cells administered by R3 are not the ones that become a patient’s new neurons. The administered mesenchymal stem cells are not specifically designed to replace damaged and lost neural networks, but rather coordinate and enhance a repair response by one’s own mechanisms.
Schedule Free Consultation
Where do the stem cells and exosomes come from?
R3 Stem Cell’s regenerative biologics originate from umbilical cord tissue that has been donated after a scheduled c-section. No baby (or mother) is harmed during the C-section procedure. The umbilical cord tissue is normally discarded, but if the mother passes screening test then the umbilical cord is immediately sent to the lab.
The lab carefully processes the umbilical cord to generate large amounts of stem cells and exosomes that are of the highest quality possible. The lab team consists of multiple PhD’s working in ISO Certified, cGMP compliant clean rooms to ensure quality assurance that exceeds USA FDA standards. The proprietary production process combines the highest potency, safety and affordability for providers to confidently offer exosome procedures. Millions of dollars have been invested into the pharmaceutical grade production of the biologics including first rate clean rooms, bioreactors, nanoparticle tracking analyzers, cytometers, PCR, tangential flow machines and real time environmental monitoring. The quality assurance testing complies with screening and testing stan¬dards consistent with the American Association of Tissue Banks, cGMP standards, FDA regulations and the highest level of any regulatory agency globally.
Stem Cell Derived Exosomes
R3 Stem Cell’s Centers of Excellence globally include umbilical cord stem cell-derived exosomes with umbilical cord stem cells to provide enhanced results. Exosomes are lipid bound vesicles (acellular) produced by cells that contain a plethora of growth factors, cytokines, mRNA and other proteins.
They are exceptionally helpful in cell-to-cell communication, and very effective for reducing inflammation when they become ingested by their recipient cell. They act as shuttles to send nucleic acids and proteins to other cells, in this way, allowing cell-to-cell communication and transporting molecules among both close and distant cells. In general, these released proteins are important regulators of intracellular information.
Exosomes could be the mediators of many stem cell-associated therapeutic activities. Considering they are 100 times smaller than stem cells, they do not have any issues passing through the blood-brain-barrier to reach the brain from the bloodstream.
Is stem cell therapy safe?
After a decade of performing over 24,000 stem cell procedures worldwide, R3 knows that the regenerative procedures are safe. The quality control employed during the stem cell production is second to none, and the side effects R3 sees are usually mild to moderate and temporary.
They may include itching, dizziness, lightheadedness, low grade fever, chills, headache, nausea. These are typically temporary. If a patient has an allergic reaction to the multivitamin or a preservative, all of R3’s Centers have the medications to resolve it quickly.
One of the questions we get asked a lot is, “Will the stem cells get rejected?” The answer is NO.
MSCs do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack the co-stimulatory molecules essential for immune detection, including CD40, CD80, and CD86.
Therefore, MSCs generally have low immunogenicity and can avoid immune rejection by the recipient, which serves as the foundation for their successful application without needing to match the donor to the recipient. Scientists call this being “immunologically privileged”.
Another question often asked is “Is there a chance of a tumor forming?” Once again the answer is NO. The mesenchymal stem cells and exosomes used during treatment have never been shown to have tumor forming potential. In fact, they have been shown to be anti-tumor forming.
R3 Stem Cell offers solutions for Parkinson’s—dial (844) GET-STEM.
Treatment Protocol
For the past decade, R3 has been successfully treating patients with stem cell and exosome therapies with injection, infusion, intranasal, intrathecal and nebulizer. For PD treatment, a combination of intravenous and intrathecal is used, or possibly IV and intranasal in certain circumstances. Most patients, over 75%, begin to see improvements within three months and last between 12 and 24 months.
For PD, R3’s providers use between one to three million stem cells per kilogram. In addition, billions of stem cell exosomes are included. Safety is paramount with the biologics products being rigorously tested prior to use, and expert providers managing each treatment as if you are a family member!
Why does R3 Stem Cell use donor tissue for its stem cells?
Although autologous (your own) stem cells provide significant advantages, allogeneic (donor) stem cells have more advantages. First of all, autologous MSCs need a long time to culture and expand, which limits its application in treatment, while allogeneic stem cells can be obtained and expanded more quickly, thus avoiding the delay of time window.
Second, age is a factor that affects the physiological characteristics of MSCs. Studies have shown that stem cells from elderly donors have decreased proliferation and differentiation ability. This means they are less in number and less effective!
Affordability
Stem cell therapy for PD may be the key step in achieving a stoppage of disease progression along with functional improvements, and we want to make it affordable for as many individuals as possible. Our global volume has allowed us to keep our patient costs as low as possible. Especially considering that most patients will need repeat therapies every one to two years, treatment cost is extremely important.
Unfortunately, stem cell clinics in Colombia, China and Panama charge over $20,000 USD for PD treatment.
How are individuals supposed to budget for that?? R3 Stem Cell’s fees are less than half that for full treatment, which also includes free exosomes, PRP and a multivitamin infusion!
R3’s Experience
For the past decade, R3 Stem Cell’s Centers globally have performed over 24,000 regenerative procedures in six countries. Patient satisfaction across all conditions treated is very high, at 85%. However, MSC treatment for PD is a MUCH newer option, so satisfaction percentages haven’t been definitively established.
R3 combines safety, effectiveness and affordability for the therapies. Internationally, the Intellicell is used, which is culturing the most active mesenchymal stem cells to create the “smartest” stem cell in the world!
R3 Stem Cell offers free consultations for individuals to discuss whether regenerative therapy is indicated for your PD. Simply call (844) GET-STEM to schedule yours
References
David Greene, MD, PhD, MBA, Founder/CEO
R3 Stem Cell offers treatments that bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with patients being able to get back to desired activities.
Founder and CEO David Greene, MD, PhD, MBA writes extensively on regenerative medicine and gives many seminars worldwide on a regular basis. With over forty Centers of Excellence globally, R3 is at the forefront of regenerative therapies.
R3’s Centers have successfully performed over 24,000 regenerative procedures to date. Call today for your free consultation (844) GET-STEM!
No portion of this Document may be reproduced without the Express Written Consent of R3 Stem Cell.
About R3 Stem Cell Disclaimer: This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental. Any claims made in the Guide refer to procedures performed outside the USA.
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
Disclaimer: The city links above provide general information on stem cell treatment. To find an R3 Stem Cell clinic near you click here
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2025 R3 Stem Cell. All Rights Reserved.
